Buradasınız

Anasayfa » Content

Hematolojik Maligniteli Hastaların Febril Nötropenik Ataklarında Vorikonazolün Yan Etkilerinin Değerlendirilmesi

Evaluating of Side Effects of Voriconazole in Febrile Neutropenic Episodes of Patients with Hematologic Malignancy

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2009

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
In neutropenic patients with hematologic malignancy, fungal infections still have been important cause of morbiditiy and mortality. Voriconazole, new developed a second generation triazol group broad spectrum antifungal, is effective in aspergillus, candida, fusarium and scedosporium infections. Alongside parenteral form of drug, oral form also have been present. During conventional amphotericin B infusion; adverse reactions like hypokalemia, nephrotoxicity and infusion reactions like fever and chill are frequently seen. In our study 30 febrile neutropenic episodes of total 23 patients with high risk hematologic malignancy admitted to our hematology clinic between date of June 2006-January 2009 were retrospectively analysed. Voriconazole had been started because of no replying to other antifungals in 11 episodes (%36,6), seconder profilaxis in 7 episodes (%23,3) and serious advers effects araising from other antifungals resulting in discontinuing this treatment in 12 episodes (%40). Advers effects associated with voriconazole were mild to intermediate hypokalemia in 2 episodes (%6,6), nefrotoxicity in 1 episode (%3,3), hepatotoxicity in 2 episodes (%6,6), visual halusination in 1 episode (%3,3). It has been suggested that voriconazol has acceptable advers effect profile in patients with hematologic malignancy
Bookmark/Search this post with
Abstract (Original Language): 
Hematolojik maligniteli febril nötropenik hastalarda, fungal enfeksiyonlar hala önemli morbidite ve mortalite nedenidirler. Vorikonazol, yeni geliştirilen geniş spektrumlu ikinci jenerasyon triazol grubu antifungal olup, aspergillus, candida, fusarium ve scedosporium enfeksiyonlarında etkilidir. İlacın parenteral formunun yanında oral formu da bulunmaktadır. Konvansiyonel amfoterisin B’nin infüzyonu sırasında ateş, titreme gibi infüzyonla ilişkili reaksiyonlar ve hipokalemi, nefrotoksisite gibi yan etkilerle sıkça karşılaşılmaktadır. Çalışmamızda Hematoloji Kliniğimizde Haziran 2006-Ocak 2009 tarihleri arasında yatan hematolojik maligniteli toplam 23 hastanın vorikonazol kullanılmış olan 30 febril nötropeni (FEN) atağını geriye dönük olarak değerlendirdik. Vorikonazol tedavisi 11 atakta (%36,6) kullanılan diğer antifungallere yanıtsızlık, 7 atakta (%23,3) sekonder profilaksi, 12 atakta ise (%40) diğer antifungallere bağlı tedaviyi bıraktıracak derecede ciddi yan etki ortaya çıkması nedeni ile başlandı. Vorikonazole bağlı yan etki olarak, 2 atakta hafif–orta derecede hipokalemi (%6,6), 1 atakta nefrotoksisite (%3,3), 2 atakta hepatotoksisite (%6,6), 1 atakta vizüel halüsinasyon (%3,3) tesbit edildi. Vorikonazolun, hematolojik maligniteli hastalarda kabul edilebilir yan etki profiline sahip olduğu kanaatine varıldı.
FULL TEXT (PDF): 
PDF icon arastirmax-hematolojik-maligniteli-hastalarin-febril-notropenik-ataklarinda-vorikonazolun-yan-etkilerinin-degerlendirilmesi.pdf
  • 3
137-141
  • Turkish

REFERENCES

References: 

1. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole
versus amphotericin B for primary therapy of invasive
aspergillosis. N Engl J Med. 2002;347:408-15.
2. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared
with liposomal amphotericin B for empirical antifungal therapy
in patients with neutropenia and persistent fever. N Engl J Med.
2002;346(4):225-34.
3. Ally R, Schürmann D, Kreısel W et al. A randomized, doubleblind, double-dummy, multicenter trial of voriconazole and
fluconazole in the treatment of esophageal candidiasis in
immunocompromised patients. Clin Infect Dis. 2001;33:1447-
145.
4. Denning DW, Griffiths CE. Mucocutaneous retinoid-effects
and facial erythema related to the novel triazole antifungal
agent voriconazole. Clin Exp Dermatol. 2001;26(8):648-53.
5. Dolan CK, Hall MA, Blazes DL, Norwood CW.
Pseudoporphyria as a result of voriconazole use: a case report.
Int J Dermatol. 2004;43(10):768-71.
6. Potoskı BA, Brown J. The safety of voriconazole. Clin Infect
Dis. 2002;35:1273-5.
7. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of
voriconazole in the treatment of acute invasive aspergillosis.
Clin Infect Dis. 2002;34(5):563-71.
8. Aksoy F, Akdoğan E, Aydın K et al. Voriconazol-Induced
Neuropathy. Chemotheraphy. 2008;54:224-7.
9. Kofla G, Ruhnke M. Voriconazole: review of a broad spectrum
triazole antifungal agent. Expert Opin Pharmacother.
2005;6(7):1215-29.
10. Imbof A, Schaer DF, Schwarz U, Schanz U. Neurological
adverse events to voriconazole: evidence for therapeutic drug
monitoring. Swiss Med Wkly. 2006;136:739-42.
11. Peman J, Salavert M, Canton E et al. Voriconazole in the
management of nosocomial invasive fungal enfections. Ther
Clin Risk Manag. 2006;2(2):129-58.
12. Cowen EW, Nguyen JC, Miller DD et al. Chronic phototoxicity
and aggressive squamous cell carcinoma of the skin in children
and adults during treatment with voriconazole. J Am Acad
Dermatol 2009; 5:1-7.
13. Scott LJ, Simpson D. Voriconazole: A review of its use in the
management of invasive fungal infections. Drugs.
2007;67(2):269-98.
14. De Pauw B, Walsh TJ, Donnelly JP et al. Revised Definitions
of Invasive Fungal Disease from the European Organisation for
Research and Treatment of Cancer/Invasive Fungal infections
Cooperative Group and the National Institute of Allergy and
Infectious Diseases Mycoses Study Group (EORTC/MSG)
Consensus Group Clin Infect Dis. 2008;46:1813-21.

Thank you for copying data from http://www.arastirmax.com